



**FOR IMMEDIATE RELEASE**

December 1, 2023

## **INDEPENDENT PROGRAM ADMINISTRATOR ISSUES ANNUAL REPORT**

Major League Baseball (MLB) and the Major League Baseball Players Association (MLBPA) today released the annual public report from the Joint Drug Prevention and Treatment Program's Independent Program Administrator. The Joint Drug Prevention and Treatment Program calls for a public report to be issued each year.

The accompanying report from the Independent Program Administrator, Thomas M. Martin, Ph.D., covers the period from the beginning of the 2022-2023 off-season through the end of Major League Baseball's 2023 Postseason.

# # #

**Contact:** Michael Teevan or Donald Muller, Major League Baseball, (212) 931-7878, [mlbpressbox.com](http://mlbpressbox.com), [@MLB\\_PR](https://twitter.com/MLB_PR); Silvia Alvarez, Major League Baseball Players Association, (212) 826-0808, [mlbplayers.com](http://mlbplayers.com), [@MLBPA](https://twitter.com/MLBPA).



## 2023 Public Report of Major League Baseball's Joint Drug Prevention and Treatment Program

This report covers the time from the beginning of the 2022-2023 off-season to the end of the 2023 post-season (the "2023 Reporting Period"). As per agreement between the Office of the Commissioner of Baseball and the Major League Baseball Players Association, the following report is specific to Players on the 40-man rosters for Major League Baseball Clubs.

- 1) The total number of drug tests that were conducted during the 2023 Reporting Period was 11,783. Of this total number, 9,550 were urine samples that were collected and analyzed for Performance Enhancing Substances, Stimulants, DHEA, Diuretics, Masking Agents, and Drugs of Abuse. The number of dried blood spot samples that were collected and analyzed for the presence of human growth hormone (hGH) was 2,233.
- 2) One (1) adverse analytical finding was reported by the UCLA Laboratory and resulted in discipline. This single finding was for Stanozolol, a Performance Enhancing Substance.
- 3) Sixty-five (65) Therapeutic Use Exemptions were granted. The diagnoses were as follows:

Attention Deficit Hyperactivity Disorder: 61  
Hypertension: 1  
Sleep disorder: 1  
Hormone function: 1  
Uveitis/High eye Pressure: 1

Respectfully submitted,

*Thomas M. Martin*

Thomas M. Martin, Ph.D.  
Independent Program Administrator  
Major League Baseball's Joint Drug Prevention and Treatment Program